TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be non-pregnant, non-lactating, and either be post-menopausal for at least 12 months, have documentation of irreversible surgical sterilization, or confirm the use of one of the acceptable contraceptive methods~* Males must agree to avoid fathering a child and agree to use an appropriate method of contraception~* Chronic maintenance hemodialysis 3x a week for at least 3 months~* Chronic maintenance peritoneal dialysis for a minimum of 6 months~* Kt/V ≥ 1.2 at most recent measurement prior to screening~* Prescribed and taking at least 3 doses of phosphate binder per day~* Serum phosphorus levels should be between 4.0 and 8.0 mg/dL at screening~* Unchanged dose of vitamin D or calcimimetics for the last 4 weeks prior to screening~* For enrollment in the study after at least 2 weeks of wash-out, subjects must have serum phosphorus levels of at least 6.0 mg/dL but not more than 10.0 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value after 2 or 3 weeks wash-out of phosphate binders~Exclusion Criteria:~* Severe hyperphosphatemia defined as serum phosphorus greater than 10.0 mg/dL on phosphate-binders at any time point during clinical routine monitoring for the 3 preceding months before screening visit~* Serum/plasma parathyroid hormone \>1200 pg/mL~* Clinical signs of hypovolemia at enrollment~* History of IBD or IBS-D~* Scheduled for living donor kidney transplant, change to peritoneal dialysis, home HD or plans to relocate to another center during the study period~* Positive serology with evidence of significant hepatic impairment or WBC elevation according to the Investigator~* Life expectancy \<6 months~* Previous exposure to tenapanor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tenapanor 10 mg, 20 mg, 30 mg BID (Type: EXPERIMENTAL): During the 26-week open label part, all enrolled subjects will receive 30 mg BID doses of tenapanor. Investigators may decrease or increase the dose in 10 mg increments to a minimum of 10 g BIDor a maximum of 30 mg BID
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Sevelamer Carbonate (Type: ACTIVE_COMPARATOR): Subjects randomized into the active control group, for safety analysis, will receive sevelamer carbonate, open label, for the entire 52-week study period. Sevelamer carbonate will be dosed based on package insert instructions (standard of care)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* CABG candidate~* At least 4 akinetic segments~* First anterior heart attack within in 10 days to 3 month.~* St elevation MI defined by: Post Acute MI LVEF less than 45% as assessed by echocardiography.~* The target lesion had to be located in the left anterior descending (LAD) section.~Exclusion Criteria:~* History of prior anterior myocardial infarction:~* History of prior CABG~* Poor echocardiography window.~* Active infection or history of recurrent infection or positive test for syphilis (RPR), hepatitis B and C (HBSAg/ Anti HBc Anti - Hcv) HIV and HTLV-l~* Documental terminal illness or malignancy.~* Previous bone marrow transplant~* Autoimmune disease (e. g Lupus, Multiple sclerosis)~* Any contraindication for bone - marrow aspiration.~* Positive pregnancy test (in women with child bearing potential)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MNC implantation (Type: EXPERIMENTAL): Implantation of BM derived MNC
- AC 133 implantation (Type: EXPERIMENTAL): Implantation of BM derived AC 133
- Control (Type: PLACEBO_COMPARATOR): Injection of cell carrier

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have received a diagnosis of SLE at least 24 weeks prior to screening, meeting the American College of Rheumatology (ACR) 1982 revised criteria OR the 2012 Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria.~* Have a positive antinuclear antibody (ANA) (titer ≥1:80) and/or a positive anti-double-stranded deoxyribonucleic acid (dsDNA) as assessed by a central laboratory at screening.~* Have a SLEDAI-2K score ≥4 based on clinical symptoms (not including lab values) at randomization.~* Have active arthritis and/or active rash as defined by the SLEDAI-2K at randomization.~Exclusion Criteria:~* Have active severe lupus nephritis.~* Have active severe central nervous system (CNS) lupus.~* Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking investigational product or interfere with the interpretation of data.~* Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection.~* Are currently receiving oral corticosteroids at doses \>20-milligrams per day of prednisone (or equivalent) or have adjusted the dose of corticosteroids within 2 weeks of planned randomization.~* Have started treatment with or adjusted the dose of nonsteroidal anti-inflammatory drugs (NSAIDs) (for which the NSAID use is intended for treatment of signs and symptoms of SLE) within 4 weeks of planned randomization.~* Have started treatment with or adjusted the dose of an antimalarial within 12 weeks of planned randomization.~* Have started treatment with or adjusted the dose of an immunosuppressant within 12 weeks of planned randomization.~* Have received cyclophosphamide (or any other cytotoxic agent) within 12 weeks prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 mg Baricitinib (Type: EXPERIMENTAL): Participants received 2 (milligrams) mg of Baricitinib tablet orally once a day for 24 weeks.
- 4 mg Baricitinib (Type: EXPERIMENTAL): Participants received 4 mg of Baricitinib tablet orally once a day for 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received Placebo orally once daily (QD) for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Early and advanced Idiopathic Parkinson Disease with early morning motor impairment~Exclusion Criteria:~* Atypical Parkinsonian syndromes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rotigotine (Type: EXPERIMENTAL): Rotigotine transdermal patch
- Placebo (Type: PLACEBO_COMPARATOR): Placebo transdermal patch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Male or female patients aged 40 years or over with moderate to severe chronic obstructive pulmonary disease (COPD) plus~* 20 pack-year smoking history~* Signed informed consent~* Post-bronchodilator forced expiratory volume in 1 second )FEV1) ≥ 30% and \< 80% predicted FEV1/FVC (forced vital capacity) \< 70%~Exclusion Criteria include:~* History of asthma~* Prior exposure to indacaterol~* Active cancer or history of cancer~* Patients with concomitant pulmonary disease~* Patients with diabetes Type I or uncontrolled diabetes Type II~* Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured at screening or randomization is prolonged~* Patients unable to successfully use a dry-powder inhaler device or perform spirometry measurements~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 150 μg (Type: EXPERIMENTAL): Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
- Placebo to indacaterol (Type: PLACEBO_COMPARATOR): Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Debio 1450 for Bacterial Skin Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has clinically documented infection of the skin or skin structure suspected or documented to be caused by a staphylococcal pathogen~* Meets other protocol-specified criteria for qualification and contraception~* Is willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related to food, drink and medications~* Voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures~Exclusion Criteria:~* Has history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters~* Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:~  1. the safety or well-being of the participant or study staff;~ 2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding);~ 3. the analysis of results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Debio 1450 320/480 mg (Type: EXPERIMENTAL): After 2 doses of Debio 1450 IV (intravenous) therapy, the Debio 1450 320/480 mg daily dose group receives 240 mg Debio 1450 Oral + Linezolid Placebo twice daily (BID).
- Debio 1450 160/240 mg (Type: EXPERIMENTAL): After 2 doses of Debio 1450 IV therapy, the Debio 1450 160/240 mg daily dose group receives 120 mg Debio 1450 Oral + Debio 1450 Oral Placebo + Linezolid Placebo BID.
- Placebo (Type: PLACEBO_COMPARATOR): After 2 doses of Vancomycin IV, the Placebo comparator group receives Debio 1450 Oral Placebo + Linezolid 600 mg BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparator Study of LT-NS001 in Healthy Subjects With Endoscopic Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI 18-30 kg/m2~* No NSAID's for 14 days prior to baseline endoscopy~Exclusion Criteria:~* Pregnant/Nursing women~* History of documented gastroduodenal ulcer

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Treated with stable metformin with or without a sulfonylurea (metformin ≥1000 milligrams/day; sulfonylurea should be at least half the maximum dose) for at least 2 months~* Are insulin-naive (except for the use of insulin for treatment of gestational diabetes or short-term use \[≤14 consecutive days\] for acute conditions)~* HbA1c ≥7.5% to ≤11.0% at screening~* Stable weight (±5%) ≥3 months, and agree to not initiate a diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment~* Body mass Index (BMI) ≥23 kilograms per meter squared~Exclusion Criteria:~* Type 1 diabetes mellitus~* Have history of chronic or acute pancreatitis~* Have history of proliferative diabetic retinopathy; or diabetic maculopathy; or non-proliferative diabetic retinopathy that requires acute treatment~* Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months~* Have a history of ketoacidosis or hyperosmolar state/coma~* Have a known clinically significant gastric emptying abnormality, have undergone or plan to have during the course of the study, or chronically take drugs that directly affect GI motility~* Have acute myocardial infarction (MI), stroke or hospitalization due to congestive heart failure (CHF) within 2 months~* Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)~* Have been treated with prescription drugs that promote weight loss or similar other body weight loss medications including over the counter (OTC) within 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 mg Tirzepatide (Type: EXPERIMENTAL): Participants received 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW).
- 10 mg Tirzepatide (Type: EXPERIMENTAL): Participants received 10 mg tirzepatide administered SC QW.
- 15 mg Tirzepatide (Type: EXPERIMENTAL): Participants received 15 mg tirzepatide administered SC QW.
- Insulin Glargine (Type: ACTIVE_COMPARATOR): Participants received insulin glargine administered once daily (QD) SC. The starting dose of insulin glargine was 6 Insulin Units (IU)/day at bedtime, titrated to a fasting blood glucose (FBG) between 72-100 milligrams per Deciliter (mg/dL), following a treat-to-target (TTT) algorithm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Korean patients aged ≥ 20 years of age at the day of obtaining the informed consent~* Patients with histologically confirmed diagnosis of the following:~  * PTCL, not otherwise specified (PTCL-NOS)~ * Anaplastic Large Cell Lymphoma (ALCL ALK-positive/negative)~ * Angioimmunoblastic T-cell Lymphoma (AITL)~* Have relapsed or refractory to at least one prior systemic chemotherapy for the above disease (currently requiring therapy)~* Have at least 1 evaluable lesion~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2~* Life expectancy of at least 3 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SP-02L (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age≥18 years~* Confirmed G1, G2 or G4 HCV infection~* Plasma HCV-RNA ≥1000 IU/mL~* No history of HCV treatment of any kind~* Willingness to use a birth control method (hormonal or intrauterine device for women, condoms for men), starting before HCV treatment initiation and continued until 4months (women) and 7 months (men) after end of treatment.~* Weight ≥40 kg and ≤125 kg~For patients infected with HIV :~* Confirmed HIV-1 infection~* Stable HIV treatment for at least 8 weeks with two NRTIs (tenofovir or abacavir, and lamivudine or emtricitabine) and a third agent (raltegravir, lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir, efavirenz, nevirapine)~* Current CD4+ lymphocytes count ≥100/mm3~* Current plasma HIV-1 RNA \<200 copies/mL~Exclusion Criteria:~For each patient:~* Cirrhosis classified Child-Pugh B or C~* Co-infection by the Hepatitis B virus~* Pregnant or breastfeeding ongoing~* History of transplantation of organs or tissues~* Progressive Cancer, including hepatocellular carcinoma~* Epilepsy~* Sickle Cell Disease~* A history of myocardial infarction or other severe heart disease~* Excessive consumption of alcohol or drug users, in the absence of substitution by methadone, a stable weaning for more than three months should be required~* Ongoing Participation in another clinical trial~* Contraindications to the Sofosbuvir as defined in the Summary of Product Characteristics~* At least one of the following laboratory abnormalities:~Haemoglobin \<10 g / 100 ml (woman) \<11 g / 100 ml (man) Platelet count \<50,000 / mm3 polymorphonuclear neutrophils rate \<750 / mm3 Creatinine clearance \<50ml / min~For patients infected with HIV:~* Severe opportunistic infections in the last 6 months~* Poor adherence to antiretroviral treatment history~* Use of antiretroviral drugs other than those permitted in the test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sofosbuvir+Ribavirin (Type: EXPERIMENTAL): Sofosbuvir 400mg QD (Sovaldi®) + Ribavirin weight-adjusted dosing (1000mg BID in patients \< 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
- Sofosbuvir+Ledipasvir (Type: EXPERIMENTAL): Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of RA for at least 3 months prior to screening~* Have no history of latent or active tuberculosis (TB) and test negative for TB~Exclusion Criteria:~* Have inflammatory diseases other than RA~* Have been treated with disease-modifying anti-rheumatic drugs (DMARDs)/systemic immunosuppressives other than methotrexate (MTX), sulfasalazine, or hydroxychloroquine during the 4 weeks prior to the first administration of study agent~* Have received intramuscular (IM), IV, or intra-articular corticosteroids within 4 weeks of study agent administration~* Have a known hypersensitivity to human Ig proteins~* Have received infliximab, golimumab, adalimumab or abatacept within 3 months, or etanercept or anakinra within 1 month prior to the first administration of study agent~* Have received alefacept, efalizumab, natalizumab, rituximab, or any B-cell-depleting agent~* Have been treated with any other biologics or investigational drugs, within 5 half-lives of that drug prior to the first administration of study agent~* Have a history of latent or active granulomatous infection, including tuberculosis (TB), histoplasmosis, or coccidioidomycosis, prior to screening~* Have had a Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening~* Have had a serious infection (eg, hepatitis, pneumonia, pyelonephritis, or sepsis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Golimumab IV infusions of 2 mg/kg golimumab on Days 1 and 85.
- 002 (Type: EXPERIMENTAL): Golimumab SC injection of 100 mg every 4 weeks through Week 20

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete